Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions

Journal of Thrombosis and Thrombolysis

Volumn 25, Issue 3, 2008, Pages 239-246

  Gulmez, Oyku ^a   Yildirir, Aylin ^a   Kaynar, Gamze ^a   Konas, Didem ^a   Aydinalp, Alp ^a   Ertan, Cagatay ^a   Ozin, Bulent ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Aspirin resistance; Cardiac troponins; CK MB; PFA 100; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COLLAGEN; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TROPONIN I;

ADULT; AGED; ANALYZER; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ASSAY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE FUNCTION; THROMBOEMBOLISM;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NECROSIS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TABLETS, ENTERIC-COATED; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TROPONIN I; UP-REGULATION;

EID: 44649193776     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0067-z     Document Type: Article

References (41)

1. Abdelmeguid AE, Topol EJ (1996) The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation 94:3369-3375
2. Califf RM, Abdelmeguid AE, Kuntz RE et al (1998) Myonecrosis after revascularization procedures. J Am Coll Cardiol 31:241-251
3. Kanaparti PK, Brown DL (2000) Relation between coronary atherosclerotic plaque burden and cardiac enzyme elevation following percutaneous coronary intervention. Am J Cardiol 86:619-622
4. Garbatz E, Iung B, Lefevre G et al (1999) Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. Am J Cardiol 34:663-671
5. Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358:527-533
6. Steinhubl SR, Berger PB, Mann JT 3rd et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 288:2411-2420
7. Popma JJ, Weitz J, Bittl JA et al (1998) Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 114:728S-741S
8. Patrono C, Coller B, Dalen JE et al (2001) Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 119:39S-63S
9. Sanderson S, Emery J, Baglin T et al (2005) Narrative review: Aspirin resistance and its clinical implications. Ann Intern Med 142:370-380
10. Patrono C (2003) Aspirin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 1:1710-1713
11. Mason PJ, Freedman JE, Jacobs AK (2004) Aspirin resistance: Current concepts. Rev Cardiovasc Med 5:156-163
12. Mason PJ, Jacobs AK, Freedman JE (2005) Aspirin resistance and atherothrombotic disease. JACC 6:986-993
13. Tantry US, Bliden KP, Gurbel PA (2005) Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46:1705-1709
14. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK (2006) on behalf of the platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis platelet function analyzer (PFA-100) closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4:312-319
15. Mammen EF, Comp PC, Gosselin R et al (1998) PFA-100 system: A new method for assessment of platelet dysfunction. Semin Thromb Hemost 24:195-202
16. Andersen K, Hurlen M, Arnesen H et al (2003) Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108:37-42
17. Homoncik M, Jilma B, Hergovich N et al (2000) Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83:316-321
18. Chen WH, Lee PY, Ng W et al (2004) Aspirin resistance is associated with high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43:1122-1126
19. Coma-Canella I, Velasco A, Castano S (2005) Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 101:71-76
20. Harrison P, Robinson MS, Mackie IJ et al (1999) Performance of the platelet function analyzer PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 10:25-31
21. Heilmann EJ, Kundu SK, Sio R, Garcia C et al (1997) Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 87:159-164
22. Favaloro EJ (2002) Clinical application of the PFA-100. Curr Opin Hematol 9:407-415
23. Hochholzer W, Trenk D, Bestehorn HP et al (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. JACC 48:1742-1750
24. Gum PA, Koltke-Marchant K, Poggio ED et al (2001) Profile and prevalance of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235
25. Wang JC, Aucoin-Barry D, Manuelian D et al (2003) Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92:1492-1494
26. Abaci A, Caliskan M, Bayram F et al (2006) A new definition of aspirin non-responsiveness by Paltelet Function analyzer-100 TM and its predictors. Platelets 17:7-13
27. Nageh T, Sherwood RA, Harris BM et al (2003) Cardiac troponin T and I and creatine-kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int J Cardiol 92:285-293
28. Kini AS, Lee P, Marmur JD et al (2004) Correlation of postpercutaneous coronary intervention creatine-kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 93:18-23
29. Kini A, Marmur J, Kini S et al (1999) Creatine-kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a bening clinical course. J Am Coll Cardiol 34:663-671
30. Fuchs S, Kornowski R, Mehran R et al (2000) Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 85:1077-1082
31. Adams JE, Bodor GS, Devile-Roman VG et al (1993) Cardiac Troponin I: A marker with high specificity for cardiac injury. Circulation 88:101-106
32. Amsterdam EA, Lewis WR (1998) Identification of low risk patients with chest pain in emergency department: Another look at cardiac troponins. J Am Coll Cardiol 32:15-16
33. Varani E, Balducelli M, Vecchi G et al (2005) Occurence of non-Q myocardial infarction following percutaneous coronary intervention in the stent era: Systematic monitoring of the three markers of myocardial necrosis. J Interv Cardiol 18:243-248
34. Gurbel PA, Bliden KP, Zaman KA et al (2005) Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (clear platelets) study. Circulation 111:1153-1159
35. Kastarati A, Mehilli J, Schühlen H et al (2004) A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350:232-238
36. Mehilli J, Kastrati A, Schühlen H et al (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Circulation 110:3627-3635
37. Hankey GJ, Eikelboom JW (2006) Aspirin resistance. Lancet 367:606-617
38. Eikelboom JW, Hirsh J, Weitz JI, et al (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655
39. Gum PA, Kottke-Marchant K, Welsh PA et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965
40. Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder A pilot-study including 180 post-stroke patients. Thromb Res 71:397-403
41. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K (2002) Towards a definition of aspirin resistance: A typological approach. Platelets 13:37-40